NO930305L - Anvendelse av canp-inhibitorer i farmasoeytiske preparater - Google Patents

Anvendelse av canp-inhibitorer i farmasoeytiske preparater

Info

Publication number
NO930305L
NO930305L NO93930305A NO930305A NO930305L NO 930305 L NO930305 L NO 930305L NO 93930305 A NO93930305 A NO 93930305A NO 930305 A NO930305 A NO 930305A NO 930305 L NO930305 L NO 930305L
Authority
NO
Norway
Prior art keywords
inhibitors
therapy
contraception
neutral
viral diseases
Prior art date
Application number
NO93930305A
Other languages
English (en)
Norwegian (no)
Other versions
NO930305D0 (no
Inventor
Helen Logothetou-Rella
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of NO930305D0 publication Critical patent/NO930305D0/no
Publication of NO930305L publication Critical patent/NO930305L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO93930305A 1991-06-03 1993-01-29 Anvendelse av canp-inhibitorer i farmasoeytiske preparater NO930305L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR91100238 1991-06-03
PCT/EP1992/001223 WO1992021373A1 (en) 1991-06-03 1992-06-02 USE OF CANPs-INHIBITORS IN PHARMACEUTICAL PREPARATIONS

Publications (2)

Publication Number Publication Date
NO930305D0 NO930305D0 (no) 1993-01-29
NO930305L true NO930305L (no) 1993-02-26

Family

ID=10940713

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930305A NO930305L (no) 1991-06-03 1993-01-29 Anvendelse av canp-inhibitorer i farmasoeytiske preparater

Country Status (14)

Country Link
EP (1) EP0549742B1 (de)
JP (1) JP3703828B2 (de)
AT (1) ATE263574T1 (de)
AU (1) AU646961B2 (de)
CA (1) CA2088671C (de)
DE (1) DE69233337T2 (de)
DK (1) DK0549742T3 (de)
ES (1) ES2215162T3 (de)
GR (1) GR1001044B (de)
IL (1) IL102079A (de)
NO (1) NO930305L (de)
NZ (1) NZ243003A (de)
PT (1) PT100560A (de)
WO (1) WO1992021373A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951078L (fi) * 1992-09-09 1995-03-08 Amgen Boulder Inc Retrovirusinfektion inhibitio
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
EP0626178A1 (de) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
US20030060435A1 (en) 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers

Also Published As

Publication number Publication date
AU646961B2 (en) 1994-03-10
DK0549742T3 (da) 2004-07-26
NO930305D0 (no) 1993-01-29
JP3703828B2 (ja) 2005-10-05
EP0549742B1 (de) 2004-04-07
GR1001044B (el) 1993-04-28
CA2088671A1 (en) 1992-12-04
PT100560A (pt) 1993-07-30
WO1992021373A1 (en) 1992-12-10
JPH06502188A (ja) 1994-03-10
AU1907392A (en) 1993-01-08
ATE263574T1 (de) 2004-04-15
CA2088671C (en) 1997-01-14
NZ243003A (en) 1997-07-27
DE69233337T2 (de) 2005-05-04
IL102079A (en) 1996-10-16
EP0549742A1 (de) 1993-07-07
ES2215162T3 (es) 2004-10-01
DE69233337D1 (de) 2004-05-13

Similar Documents

Publication Publication Date Title
EA199901031A1 (ru) Производные бензимидазола
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
HRP20010877B1 (hr) Pripravci za prevenciju i liječenje amiloidogenskih bolesti
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
NO20025450D0 (no) Ny farmasöytisk sammensetning
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
TR200002965T2 (tr) Enfeksiyonların terapötik ve profilaktik tedavisi için organofosforlu terkiplerin kullanımı
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
ATE386808T1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
ES2051641B1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
DE69637178D1 (de) N-chlorphenylcarbamate enthaltendes arzneimittel sowie n-chlorphenylthiocarbamate zur hemmung des wachstums von viren
NO930305D0 (no) Anvendelse av canp-inhibitorer i farmasoeytiske preparater
CA2384929A1 (en) A novel angiogenesis inhibitor
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
EP0287633A4 (de) Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
ATE263555T1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
NO20020914L (no) Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
ES2156190T3 (es) Procedimiento para la prevencion de la degradacion de la proteina c.